Aktie A3DWEE PULMATRIX, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Pulmatrix, Inc.

Aktien

A3DWEE

US74584P3010

PULM

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 03.05.2024 		% 5 Tage % 1. Jan.
1,96 USD -3,44 % Intraday Chart für Pulmatrix, Inc. -3,92 % +5,38 %
28.03. Pulmatrix, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
13.03. Pulmatrix, Inc. genehmigt die Beendigung des Arbeitsverhältnisses von Margaret Wasilewski als Chief Medical Officer CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Explores Strategic Alternatives
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Sector Update: Health Care Stocks Easing Late Tuesday
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DWEE Aktie
  4. Nachrichten Pulmatrix, Inc.
  5. Andere Sprachen